Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125

Rubini, Giuseppe; Altini, Corinna; Notaristefano, Antonio; Merenda, Nunzio; Rubini, D.; Ianora, Amato Antonio Stabile; Asabella, Artor Niccoli

doi:10.1016/j.remn.2013.06.008

Cited by 30 publications

(33 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A negative FDG PET/CT has a high-negative predictive value ( 9 ). The results of our study are comparable to the literature, with a good performance of PET/CT (Table 7 ) ( 5 , 6 , 9 , 11 , 23 , 25 , 26 , 28 , 31 , 32 ). Our study found a significant impact of PET/CT in the management of recurrent ovarian cancer (Table 8 ).…”

Section: Discussionsupporting

confidence: 89%

Clinical and Survival Impact of FDG PET in Patients with Suspicion of Recurrent Ovarian Cancer: A 6-Year Follow-Up

et al. 2015

View full text Add to dashboard Cite

BackgroundThe aim of this retrospective study was to evaluate the contribution of fluorine-18-fluoro-deoxyglucose (FDG) positron emission tomography (PET) to the clinical management and survival outcome of patients (pts) suspected of recurrent ovarian carcinoma, with the hypothesis that early diagnosis of recurrent ovarian cancer may improve overall survival (OS).MethodsFifty-three FDG PET/CT scans were retrospectively analyzed for 42 pts. CT and PET/CT findings were confirmed by imaging and clinical follow-up, and/or pathology, which were considered as the gold standard diagnosis. The treatment plan based on CT staging was compared with that based on PET/CT findings. Medical records were reviewed for pts characteristics, progression-free survival (PFS), and OS. PFS and OS were analyzed using the Cox proportional hazards regression model.ResultsThe final diagnosis of recurrence was established pathologically (n = 16), or by a median clinical follow-up of 6.5 years (range 0.5-7.5) after the PET/CT (n = 37). PET/CT provided a higher detection sensitivity (92.2%, 47/51) than CT (60.8%, 31/51) (p < 0.001). Globally, PET/CT modified the treatment plan in 56.6% (30/53) and in 65.2% (15/23) when the CT was negative prior to PET/CT. In 30 cases, those benefited from a modified treatment plan, these changes led to the intensification of a previous treatment procedure in 83.3% (25/30), and to a reduction in the previous treatment procedure in 16.6% of cases (5/30). The Cox regression multivariate analysis showed that the number of lesions visualized by CT and presence of lung lesions detected by PET/CT were significantly associated with PFS (p = 0.002 and p = 0.035, respectively).ConclusionOn account of its impact on treatment planning, and especially in predicting patient outcome, FDG PET is a valuable diagnostic tool for cases of suspected ovarian cancer recurrence.

show abstract

Section: Discussionsupporting

confidence: 89%

Clinical and Survival Impact of FDG PET in Patients with Suspicion of Recurrent Ovarian Cancer: A 6-Year Follow-Up

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The studies were conducted in America, Asia and Europe between 1993 and 2014. Fifteen studies (657 patients) considered the diagnostic performance of PET and 49 studies (3065 patients) analyzed the diagnostic value of PET/CT . The mean or median age of most patients was between 45 and 60.…”

Section: Resultsmentioning

confidence: 99%

Diagnostic value of positron emission tomography (PET) and PET/computed tomography in recurrent/metastatic ovarian cancer: A meta‐analysis

Jiang

et al. 2017

J of Obstet and Gynaecol

View full text Add to dashboard Cite

show abstract

“…Of these, two studies used ce PET/CT for analysis[1223] and the rest of the studies used ld PET/CT for analysis. [242526272829]…”

Section: Evidence Synthesismentioning

confidence: 99%

“…Therefore, there were three studies[242527] and 184 patients that analyzed peritoneal carcinomatosis for staging of OCs and achieved pooled sensitivity of 86.78%. We were not able to calculate pooled specificity as we did not have information on the number of benign cases in one of the studies.…”

Section: Evidence Synthesismentioning

confidence: 99%

Systematic review on the accuracy of positron emission tomography/computed tomography and positron emission tomography/magnetic resonance imaging in the management of ovarian cancer: Is functional information really needed?

et al. 2017

View full text Add to dashboard Cite

Ovarian cancer (OC) often presents at an advanced stage with frequent relapses despite optimal treatment; thus, accurate staging and restaging are required for improving treatment outcomes and prognostication. Conventionally, staging of OC is performed using contrast-enhanced computed tomography (CT). Nevertheless, recent advances in the field of hybrid imaging have made positron emission tomography/CT (PET/CT) and PET/magnetic resonance imaging (PET/MRI) as emerging potential noninvasive imaging tools for improved management of OC. Several studies have championed the role of PET/CT for the detection of recurrence and prognostication of OC. We provide a systematic review and meta-analysis of the latest publications regarding the role of molecular imaging in the management of OC. We retrieved 57 original research articles with one article having overlap in both diagnosis and staging; 10 articles (734 patients) regarding the role of PET/CT in diagnosis of OC; 12 articles (604 patients) regarding staging of OC; 22 studies (1429 patients) for detection of recurrence; and 13 articles for prognostication and assessment of treatment response. We calculated pooled sensitivity and specificity of PET/CT performance in various aspects of imaging of OC. We also discussed the emerging role of PET/MRI in the management of OC. We aim to give the readers and objective overview on the role of molecular imaging in the management of OC.

show abstract

Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125

Cited by 30 publications

References 17 publications

Clinical and Survival Impact of FDG PET in Patients with Suspicion of Recurrent Ovarian Cancer: A 6-Year Follow-Up

Clinical and Survival Impact of FDG PET in Patients with Suspicion of Recurrent Ovarian Cancer: A 6-Year Follow-Up

Diagnostic value of positron emission tomography (PET) and PET/computed tomography in recurrent/metastatic ovarian cancer: A meta‐analysis

Systematic review on the accuracy of positron emission tomography/computed tomography and positron emission tomography/magnetic resonance imaging in the management of ovarian cancer: Is functional information really needed?

Contact Info

Product

Resources

About